<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intravenous antimicrobial regimens for anthrax meningitis or systemic anthrax when meningitis has not been excluded*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intravenous antimicrobial regimens for anthrax meningitis or systemic anthrax when meningitis has not been excluded*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Intravenous antimicrobial regimens for anthrax meningitis or systemic anthrax when meningitis has not been excluded*</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Nonpregnant adults<sup>¶</sup></td> <td class="subtitle1">Children and adolescent<br/> (age ≥1 month through 17 years)</td> </tr> <tr> <td class="subtitle2_left" colspan="2">First bactericidal agent:</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Preferred:</td> </tr> <tr> <td class="indent2">Ciprofloxacin 400 mg every 8 hours</td> <td>Ciprofloxacin 30 mg/kg per day divided every 8 hours, not to exceed 400 mg per dose</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Alternatives if ciprofloxacin is unavailable or contraindicated, in order of preference:</td> </tr> <tr> <td class="indent2">Levofloxacin 750 mg every 24 hours <strong>OR</strong></td> <td>Levofloxacin <ul class="decimal_heading"> <li>&lt;50 kg: 16 mg/kg per day divided every 12 hours, not to exceed 250 mg per dose</li> <li>≥50 kg: 500 mg every 24 hours <strong>OR</strong></li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent2">Moxifloxacin 400 mg every 24 hours</td> <td>Moxifloxacin <ul class="decimal_heading"> <li>3 months to &lt;2 years: 12 mg/kg per day divided every 12 hours, not to exceed 200 mg per dose</li> <li>2 to 5 years: 10 mg/kg per day divided every 12 hours, not to exceed 200 mg per dose</li> <li>6 to 11 years: 8 mg/kg per day divided every 12 hours, not to exceed 200 mg per dose</li> <li>12 to 17 years, &lt;45 kg: 8 mg/kg per day divided every 12 hours, not to exceed 200 mg per dose</li> <li>12 to 17 years, ≥45 kg: 400 mg every 24 hours</li> </ul> </td> </tr> <tr class="divider_bottom highlight_gray_text"> <td colspan="2"><strong class="heading">PLUS</strong></td> </tr> <tr> <td class="subtitle2_left" colspan="2">Second bactericidal agent:</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Preferred for all strains, regardless of penicillin susceptibility or if susceptibility is unknown:</td> </tr> <tr> <td class="indent2">Meropenem 2 g every 8 hours</td> <td>Meropenem 120 mg/kg per day divided every 8 hours, not to exceed 2 g per dose</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Alternatives if meropenem is unavailable or contraindicated, in order of preference:</td> </tr> <tr> <td class="indent2">Imipenem 1 g every 6 hours<sup>Δ</sup></td> <td>Imipenem 100 mg/kg per day divided every 6 hours, not to exceed 1 g per dose<sup>Δ</sup> <strong>OR</strong></td> </tr> <tr> <td class="indent2"> </td> <td>Vancomycin 60 mg/kg per day divided every 8 hours, not to exceed 2 grams per dose; maintain serum trough concentration of 15 to 20 mcg/mL</td> </tr> <tr> <td class="subtitle3_left" colspan="2">Alternatives for penicillin-susceptible or ampicillin-susceptible strains<sup>◊</sup>:</td> </tr> <tr> <td class="indent2">Penicillin G 4 million units every 4 hours <strong>OR</strong></td> <td>Penicillin G 400,000 units/kg per day divided every 4 hours, not to exceed 4 million units per dose <strong>OR</strong></td> </tr> <tr class="divider_bottom"> <td class="indent2">Ampicillin 3 g every 6 hours</td> <td>Ampicillin 400 mg/kg per day divided every 6 hours, not to exceed 3 g per dose</td> </tr> <tr class="divider_bottom highlight_gray_text"> <td colspan="2"><strong class="heading">PLUS</strong></td> </tr> <tr> <td class="subtitle2_left" colspan="2">Protein synthesis inhibitor (preferred):</td> </tr> <tr> <td class="indent2">Linezolid 600 mg every 12 hours<sup>§</sup></td> <td>Linezolid<sup>§</sup> <ul class="decimal_heading"> <li>&lt;12 years old: 30 mg/kg per day divided every 8 hours, not to exceed 600 mg per dose</li> <li>≥12 years old: 600 mg every 12 hours <strong>OR</strong></li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Alternatives if linezolid unavailable or contraindicated, in order of preference:</td> </tr> <tr> <td class="indent2">Clindamycin 900 mg every 8 hours <strong>OR</strong></td> <td>Clindamycin 40 mg/kg per day divided every 8 hours, not to exceed 900 mg per dose <strong>OR</strong></td> </tr> <tr> <td class="indent2">Rifampin 600 mg every 12 hours<sup>¥</sup> <strong>OR</strong></td> <td>Rifampin 20 mg/kg per day divided every 12 hours, not to exceed 300 mg per dose<sup>¥</sup> <strong>OR</strong></td> </tr> <tr> <td class="indent2">Chloramphenicol 1 g every 6 to 8 hours<sup>‡</sup></td> <td>Chloramphenicol 100 mg/kg per day divided every 6 hours, not to exceed 1 g per dose<sup>‡</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">In addition to antimicrobial therapy, antitoxin therapy (raxibacumab, obiltoxaximab, or anthrax immunoglobulin) should also be given. Patients should be treated with IV antimicrobial therapy for at least two to three weeks and until clinically stable, whichever is longer. These recommendations are based on the susceptibilities of <em>B. anthracis</em> isolated during the 2001 bioterrorism event in the United States. In the event of another bioterrorism event, susceptibilities must be rechecked and antimicrobial therapy modified accordingly. Following completion of IV antimicrobial therapy, patients exposed to aerosolized spores warrant a prolonged course of oral antimicrobials for PEP. Refer to the related topic reviews and table on anthrax PEP for additional details.</div><div class="graphic_footnotes"><p>MIC: minimum inhibitory concentration; IV: intravenous; PEP: postexposure prophylaxis.</p>
<p>* The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.</p>
<p>¶ The treatment of pregnant, postpartum, and lactating individuals is similar to that for nonpregnant adults, except that ciprofloxacin is strongly preferred as the bactericidal agent because it crosses the placenta. If ciprofloxacin cannot be used, the regimen should include at least one other agent with transplacental passage. In addition to ciprofloxacin, agents that cross the placenta include levofloxacin, moxifloxacin, ampicillin, penicillin, rifampin, and chloramphenicol (avoid use in third trimester). Imipenem crosses the placental barrier, but safety for the fetus is not known. Doxycycline crosses the placental barrier but should be used with caution in pregnancy.</p>
<p>Pharmacokinetic data suggest that ciprofloxacin, penicillin, ampicillin, and carbapenems may require higher doses in pregnant and postpartum women than those recommended for nonpregnant adults. Consult a clinical pharmacist, if available, for guidance on dosing during pregnancy.</p>
<p>Δ Imipenem is associated with an increased risk of seizures.</p>
<p>◊ Penicillin-based antimicrobial drug use requires a high index of suspicion for emergence of resistance.</p>
<p>§ Linezolid should be used with caution in patients with thrombocytopenia because it might exacerbate it. Linezolid use for &gt;14 days has additional bone marrow toxicity.</p>
<p>¥ Rifampin is not a protein synthesis inhibitor. However, it may be used as an alternative agent based on its in vitro synergy for staphylococci in place of a protein synthesis inhibitor if they (linezolid, clindamycin) cannot be given. It has not been evaluated for <em>B. anthracis</em>.</p>
‡ Because of toxicity concerns, chloramphenicol should only be used if other options are not available.</div><div class="graphic_reference">References:
<ol>
<li>Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014; 20:e130687.</li>
<li>Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis 2014; 20:e130611.</li>
<li>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics 2014; 133:e1411.</li>
</ol></div><div id="graphicVersion">Graphic 96170 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
